Time to incorporate preemptive NUDT15 testing before starting thiopurines in inflammatory bowel disease in Asia and beyond: a review

References

• Ansari A, Arenas M, Greenfield SM, et al. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2008;28(8):973–983. doi: 10.1111/j.1365-2036.2008.03788.x
   PubMed Web of Science ®Google Scholar
• Collie-Duguid ES, Pritchard SC, Powrie RH, et al. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics. 1999;9:37–42. doi: 10.1097/00008571-199902000-00006
   PubMedGoogle Scholar
• Feuerstein J, Nguyen G, Kupfer S, et al. American Gastroenterological Association Institute Guideline on Therapeutic drug monitoring in inflammatory bowel disease. Gastroenterology. 2017;153(3):827–834. doi: 10.1053/j.gastro.2017.07.032
   PubMed Web of Science ®Google Scholar
• Coenen MJH, de Jong DJ, van Marrewijk CJ, et al. Identification of patients with variants in TPMT and dose reduction reduces hematological events during thiopurine treatment of inflammatory bowel disease. Gastroenterology. 2015;149:907–917. doi: 10.1053/j.gastro.2015.06.002
   PubMed Web of Science ®Google Scholar
• Kader HA, Wenner WJ, Telega GW, et al. Normal Thiopurine Methyltransferase levels do not eliminate 6-mercaptopurine or azathioprine toxicity in children with inflammatory bowel disease. J Clin Gastroenterol. 2000;3:409–314. doi: 10.1097/00004836-200006000-00011
   Google Scholar
• Chisick L, Oleschuk C, Bernstein CN. The utility of thiopurine methyltransferase enzyme testing in inflammatory bowel disease. Can J Gastroenterol. 2013;27(1):39–43. doi: 10.1155/2013/280860
   PubMed Web of Science ®Google Scholar
• Fargher EA, Tricker K, Newman W, et al. Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription. J Clin Pharm Ther. 2007;32(2):187–195. doi: 10.1111/j.1365-2710.2007.00805.x
   PubMed Web of Science ®Google Scholar
• Roblin X, Oussalah A, Chevaux J-B, et al. Use of thiopurine testing in the management of inflammatory bowel diseases in clinical practice: a worldwide survey of experts. Inflamm Bowel Dis. 2011;17(12):2480–2487. doi: 10.1002/ibd.21662
   PubMed Web of Science ®Google Scholar
• Komiyama T, Yajima T, Kubota R, et al. Lower doses of 6-mercaptopurine/azathioprine bring enough clinical efficacy and therapeutic concentration of erythrocyte 6-mercaptopurine metabolite in Japanese IBD patients. J Crohn’s Colitis. 2008;2:315–321. doi: 10.1016/j.crohns.2008.05.002
   Google Scholar
• Jun JB, Cho DY, Kang C, et al. Thiopurine S-methyltransferase polymorphisms and the relationship between the mutant alleles and the adverse effects in systemic lupus erythematosus patients taking azathioprine. Clin Exp Rheumatol. 2005;23:873–876.
   PubMed Web of Science ®Google Scholar
• Qiu Y, Mao R, Zhang SH, et al. Safety profile of thiopurines in Crohn disease: analysis of 893 patient-years follow-up in a Southern China cohort. Medicine. 2015;94(41):e1513. doi: 10.1097/MD.0000000000001513
   PubMed Web of Science ®Google Scholar
• Takatsu N, Matsui T, Murakami Y, et al. Adverse reactions to azathioprine cannot be predicted by thiopurine S-methyltransferase genotype in Japanese patients with inflammatory bowel disease. J Gastroenterol Hepatol. 2009;24(7):1258–1264. doi: 10.1111/j.1440-1746.2009.05917.x
   PubMed Web of Science ®Google Scholar
• Kakuta Y, Naito T, Onodera M, et al. NUDT15 R139C causes thiopurine-induced early severe hair loss and leukopenia in Japanese patients with IBD. Pharmacogenomics J. 2016;16(3):280–285. doi: 10.1038/tpj.2015.43
   PubMed Web of Science ®Google Scholar
• Yang SK, Hong M, Baek J, et al. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat Genet. 2014;46(9):1017–1020. doi: 10.1038/ng.3060
   PubMed Web of Science ®Google Scholar
• Yang JJ, Landier W, Yang W, et al. Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. J Clin Oncol. 2015;33:1235–1242. doi: 10.1200/JCO.2014.59.4671
   PubMed Web of Science ®Google Scholar
• Liang DC, Yang CP, Liu HC, et al. NUDT15 gene polymorphism related to mercaptopurine intolerance in Taiwan Chinese children with acute lymphoblastic leukemia. Pharmacogenomics J. 2016;16(6):536–539. doi: 10.1038/tpj.2015.75
   PubMed Web of Science ®Google Scholar
• Chiengthong K, Ittiwut C, Muensri S, et al. NUDT15 c.415C>T increases risk of 6-mercaptopurine induced myelosuppression during maintenance therapy in children with acute lymphoblastic leukemia. Haematologica. 2016;101:e24–6. doi: 10.3324/haematol.2015.134775
   PubMed Web of Science ®Google Scholar
• Kakuta Y, Kinouchi Y, Shimosegawa Y, et al. Pharmacogenetics of thiopurines for inflammatory bowel disease in East Asia: prospectus for clinical application of NUDT15 genotyping. J Gastroenterol. 2018;53:172–180. doi: 10.1007/s00535-017-1416-0
   PubMed Web of Science ®Google Scholar
• Asada A, Nishida A, Shioya M, et al. NUDT15 R139C-related thiopurine leukocytopenia is mediated by 6-thioguanine nucleotide independent mechanism in Japanese patients with inflammatory bowel disease. J Gastroenterol. 2016;51:22–29. doi: 10.1007/s00535-015-1142-4
   PubMed Web of Science ®Google Scholar
• Shah SA, Paradkar M, Desai D, et al. Nucleoside diphosphate- linked moiety X-type motif 15 C415T variant as a predictor for thiopurine-induced toxicity in Indian patients. J Gastroenterol Hepatol. 2017;32:620–624. doi: 10.1111/jgh.13494
   PubMed Web of Science ®Google Scholar
• Zhu X, Wang XD, Chao K, et al. NUDT15 polymorphism are better than thiopurine S-methyltransferase as predictor of risk for thiopurine induced leukopenia in Chinese patients with Crohn’s disease. Aliment Pharm Ther. 2016;44:967–975. doi: 10.1111/apt.13796
   PubMed Web of Science ®Google Scholar
• Lee YJ, Hwang EH, Park JH, et al. NUDT15 variant is the most common variant associated with thiopurine-induced early leukopenia and alopecia in Korean pediatric patients with Crohn’s disease. ‎eur J Gastroenterol Hepatol. 2016;28:475–478. doi: 10.1097/MEG.0000000000000564
   PubMed Web of Science ®Google Scholar
• Chao K, Wang X, Cao Q, et al. Combined detection of NUDT15 variants could highly predict thiopurine-induced leukopenia in Chinese patients with inflammatory bowel disease: a multicenter analysis. Inflamm Bowel Dis. 2017;23(9):1592–1599. doi: 10.1097/MIB.0000000000001148
   PubMed Web of Science ®Google Scholar
• Sato T, Takagawa T, Kakuta Y, et al. NUDT15, FTO and RUNX1 genetic variants and thiopurine intolerance among Japanese patients with inflammatory bowel disease. Intest Res. 2017;15:328–337. doi: 10.5217/ir.2017.15.3.328
   PubMedGoogle Scholar
• Sutiman N, Chen S, Ling KL, et al. Predictive role of NUDT15 variants on thiopurine-induced myelotoxicity in Asian inflammatory bowel disease patients. Pharmacogenomics. 2018;19(1):31–43. doi: 10.2217/pgs-2017-0147
   PubMed Web of Science ®Google Scholar
• Wang HH, He Y, Wang HX, et al. Comparison of TPMT and NUDT15 polymorphisms in Chinese patients with inflammatory bowel disease. World J Gastroenterol. 2018;24(8):941–948. doi: 10.3748/wjg.v24.i8.941
   PubMed Web of Science ®Google Scholar
• Shah SAV, Paradkar MU, Desai DC, et al. Preemptive NUDT15 genotyping: redefining the management of patients with thiopurine-induced toxicity. Drug Metab Pers Ther. 2018;33(1):57–60. doi: 10.1515/dmpt-2017-0038
   PubMedGoogle Scholar
• Medaboina K, Banerjee R, Vishnubhotla R, et al. NUDT15 variant can predict the development of azathioprine induced leukopenia and allow optimal dosing in Indian patients with inflammatory bowel disease (IBD). Gut. 2018;67:A88–A89.
   Web of Science ®Google Scholar
• Kojima Y, Hirotsu Y, Omata W, et al. Influence of NUDT15 variants on hematological pictures of patients with inflammatory bowel disease treated with thiopurines. World J Gastroenterol. 2018;24(4):511–518. doi: 10.3748/wjg.v24.i4.511
   PubMed Web of Science ®Google Scholar
• Walker GJ, Harrison JW, Heap GA, et al. Association of genetic variants in NUDT15 with Thiopurine-induced myelosuppression in patients with inflammatory bowel disease. JAMA. 2019;321(8):773–785. doi: 10.1001/jama.2019.0709
   PubMed Web of Science ®Google Scholar
• Akiyama S, Matsuoka K, Fukuda K, et al. Long-term effect of NUDT15 R139C on hematologic indices in inflammatory bowel disease patients treated with thiopurine. J Gastroenterol Hepatol. 2019;34:1751–1757. doi: 10.1111/jgh.14693
   PubMed Web of Science ®Google Scholar
• Schaeffeler E, Jaeger SU, Klumpp V, et al. Impact of NUDT15 genetics on severe thiopurine-related hematotoxicity in patients with European ancestry. Genet Med. 2019;21:2145–2150. doi: 10.1038/s41436-019-0448-7
   PubMed Web of Science ®Google Scholar
• Banerjee R, Ravikanth VV, Pal P, et al. NUDT15 C415T variant compared with TPMT genotyping in predicting azathioprine-induced leucopenia: prospective analysis of 1014 inflammatory bowel disease patients in India. Aliment Pharmacol Ther. 2020;52:1683–1694. doi: 10.1111/apt.16137
   PubMed Web of Science ®Google Scholar
• Grover N, Bhatia P, Kumar A, et al. TPMT and NUDT15 polymorphisms in thiopurine induced leucopenia in inflammatory bowel disease: a prospective study from India. BMC Gastroenterol. 2021;21(1):327–334. doi: 10.1186/s12876-021-01900-8
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Kato M, Hasegawa D, et al. Susceptibility to 6-MP toxicity conferred by a NUDT15 variant in Japanese children with acute lymphoblastic leukaemia. Br J Haematol. 2015;171(1):109–115. doi: 10.1111/bjh.13518
   PubMed Web of Science ®Google Scholar
• Suzuki H, Fukushima H, Suzuki R, et al. Genotyping NUDT15 can predict the dose reduction of 6-MP for children with acute lymphoblastic leukemia especially at a preschool age. J Hum Genet. 2016;61(9):797–801. doi: 10.1038/jhg.2016.55
   PubMed Web of Science ®Google Scholar
• Moriyama T, Nishii R, Perez-Andreu V, et al. NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity. Nat Genet. 2016;48(4):367–373. doi: 10.1038/ng.3508
   PubMed Web of Science ®Google Scholar
• Kim SY, Shin JH, Park JS, et al. NUDT15 p.R139C variant is common and strongly associated with azathioprine-induced early leukopenia and severe alopecia in Korean patients with various Neurological diseases. J Neurol Sci. 2017;378:64–68. doi: 10.1016/j.jns.2017.04.041
   PubMed Web of Science ®Google Scholar
• Tsuchiya A, Aomori T, Sakamoto M, et al. Effect of genetic polymorphisms of azathioprine-metabolizing enzymes on response to rheumatoid arthritis treatment. Pharmazie. 2017;72:22–28. doi: 10.1691/ph.2017.6799
   PubMed Web of Science ®Google Scholar
• van Gennep S, Konté K, Meijer B, et al. Systematic review with meta-analysis: risk factors for thiopurine-induced leukopenia in IBD. Aliment Pharmacol Ther. 2019;50:484–506. doi: 10.1111/apt.15403
   PubMed Web of Science ®Google Scholar
• Liu Y, Meng Y, Wang L, et al. Associations between the NUDT15 R139C polymorphism and susceptibility to thiopurine-induced leukopenia in Asians: a meta-analysis. Onco Targets Ther. 2018;11:8309–8317. doi: 10.2147/OTT.S177007
   PubMed Web of Science ®Google Scholar
• Wang R, Liu B, Li J, et al. Association between the c.415C > T, c.52G > A, and 36_37insGGAGTC polymorphisms of NUDT 15 and thiopurine-induced leukopenia, thiopurine intolerance, and severe hair loss: an updated meta-analysis. Drug Des Devel Ther. 2019;13:2729–2744. doi: 10.2147/DDDT.S210512
   PubMed Web of Science ®Google Scholar
• Lek M, Karczewski KJ, Minikel EV, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536(7616):285–291. doi: 10.1038/nature19057
   PubMed Web of Science ®Google Scholar
• Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical pharmacogenetics implementation consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update. Clin Pharmacol Ther. 2019;105:1095–1105.
   PubMed Web of Science ®Google Scholar
• Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68(Suppl 3):s1–s106. doi: 10.1136/gutjnl-2019-318484
   PubMed Web of Science ®Google Scholar
• Lee KM, Kim YS, Seo GS, et al. Use of thiopurines in inflammatory bowel disease: a consensus statement by the Korean Association for the Study of Intestinal Diseases (KASID). Intest Res. 2015;13(3):193–207. doi: 10.5217/ir.2015.13.3.193
   PubMedGoogle Scholar
• Yadav A, Jena A, Thakur R, et al. Fatal thiopurine toxicity: pre-emptive testing of NUDT15 415C>T polymorphism may be lifesaving in South Asian population. Drug Metab Pers Ther. 2021;36:351–352. doi: 10.1515/dmpt-2021-0120
   PubMedGoogle Scholar
• Jena A, Jha DK, Kumar-M P, et al. Prevalence of polymorphisms in thiopurine metabolism and association with adverse outcomes: a South Asian region-specific systematic review and meta-analysis. Expert Rev Clin Pharmacol. 2021 Apr;14(4):491–501.
   PubMed Web of Science ®Google Scholar
• Zong J, Batalova J. Asian immigrant in the United States. Migration Policy Institute; 2016. https://www.migrationpolicy.org/article/asian-immigrants-united-states-2014
   Google Scholar
• Platonova A, Urso G. Asian immigration to the European Union, United States and Canada: an initial comparison. J Glob Policy Gov. 2013;1(2):143–156. doi: 10.1007/s40320-012-0018-8
   Google Scholar
• Chao K, Huang Y, Zhu X, et al. Randomized clinical trial: dose optimizing strategy by NUDT15 genotyping reduces leucopenia during thiopurine treatment of Crohn’s disease. Aliment Pharmacol Ther. 2021;54:1124–1133. doi: 10.1111/apt.16600
   PubMed Web of Science ®Google Scholar
• Chang JY, Park SJ, Jung ES, et al. Genotype-based treatment with thiopurine reduces incidence of myelosuppression in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2020;18(9):2010–2018.e2. doi: 10.1016/j.cgh.2019.08.034
   PubMed Web of Science ®Google Scholar
• Wong DR, Coenen MJH, Vermeulen SH, et al. on behalf of the TOPIC recruitment team, early assessment of thiopurine metabolites identifies patients at risk of thiopurine-induced leukopenia in inflammatory bowel disease. J Crohn’s Colitis. 2017;11(2):175–184. doi: 10.1093/ecco-jcc/jjw130
   Google Scholar
• Moriyama T, Nishii R, Lin TN, et al. The effects of inherited NUDT15 polymorphisms on thiopurine active metabolites in Japanese children with acute lymphoblastic leukemia. Pharmacogenet Genomics. 2017;27(6):236–239. doi: 10.1097/FPC.0000000000000282
   PubMed Web of Science ®Google Scholar
• Winter J, Walker A, Shapiro D, et al. Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2004;20(6):593–599. doi: 10.1111/j.1365-2036.2004.02124.x
   PubMed Web of Science ®Google Scholar
• Sayani FA, Prosser C, Bailey RJ, et al. Thiopurine methyltransferase enzyme activity determination before treatment of inflammatory bowel disease with azathioprine: effect on cost and adverse events. Can J Gastroenterol. 2005;19(3):147–151. doi: 10.1155/2005/470863
   PubMed Web of Science ®Google Scholar
• Payne K, Newman WG, Gurwitz D, et al. TPMT testing in azathioprine: a ‘cost-effective use of healthcare resource’? Personal Med. 2008;6:103–113. doi: 10.2217/17410541.6.1.103
   Web of Science ®Google Scholar
• Thompson AJ, Newman WG, Elliott RA, et al. The cost-effectiveness of a pharmacogenetic test: a trial-based evaluation of TPMT genotyping for azathioprine. Value Health. 2014;17(1):22–33. doi: 10.1016/j.jval.2013.10.007
   PubMed Web of Science ®Google Scholar
• Zarca K, Chansavang A, Loriot MA, et al. Cost-effectiveness analysis of pretreatment screening for NUDT15 defective alleles. Pharmacogenet Genomics. 2020;30(8):175–183. doi: 10.1097/FPC.0000000000000410
   PubMed Web of Science ®Google Scholar
• Zeng D, Huang X, Lin S, et al. Cost-effectiveness analysis of genotype screening and therapeutic drug monitoring in patients with inflammatory bowel disease treated with azathioprine therapy: a Chinese healthcare perspective using real-world data. Ann Transl Med. 2021;9:1138–1149. doi: 10.21037/atm-21-1980
   PubMed Web of Science ®Google Scholar
• Zudeh G, Franca R, Stocco G, et al. Biomarkers for gastrointestinal adverse events related to thiopurine therapy. World J Gastroenterol. 2021;27(38):6348–6356. doi: 10.3748/wjg.v27.i38.6348
   PubMed Web of Science ®Google Scholar
• Zelinkova Z, Derijks LJ, Stokkers PC, et al. Inosine triphosphate pyrophosphatase and thiopurine s-methyltransferase genotypes relationship to azathioprine-induced myelo- suppression. Clin Gastroenterol Hepatol. 2006;4:44–49. doi: 10.1016/j.cgh.2005.10.019
   PubMed Web of Science ®Google Scholar
• Zabala-Fernandez W, Barreiro-de Acosta M, Echarri A, et al. A pharmacogenetics study of TPMT and ITPA genes detects a relationship with side effects and clinical response in patients with inflammatory bowel disease receiving Azathioprine. J Gastrointest Liver Dis. 2011;20:247–253.
   PubMed Web of Science ®Google Scholar
• Van-Dieren JM, Hansen BE, Kuipers EJ, et al. Meta- analysis: inosine triphosphate pyrophosphatase polymorphisms and thiopurine toxicity in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2007;26(5):643–652. doi: 10.1111/j.1365-2036.2007.03412.x
   PubMed Web of Science ®Google Scholar
• Stocco G, Cheok MH, Crews KR, et al. Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin Pharmacol Ther. 2009;85(2):164–172. doi: 10.1038/clpt.2008.154
   PubMed Web of Science ®Google Scholar
• Chen Z-Y, Zhu Y-H, Zhou L-Y, et al. Association between genetic polymorphisms of metabolic enzymes and azathioprine- induced myelosuppression in 1,419 Chinese patients: a retrospective study. Front Pharmacol. 2021;12:672769. doi: 10.3389/fphar.2021.672769
   PubMed Web of Science ®Google Scholar
• Jena A, Grover N, Bhatia P, et al. ITPA polymorphisms do not predict additional risk beyond TPMT and NUDT15 for thiopurine-induced cytopenia in inflammatory bowel disease, Revista de Gastroenterología de México. English ed. science direct. 2023. doi: 10.1016/j.rgmxen.2021.11.017
   Google Scholar